Author + information
- Received May 7, 2017
- Revision received June 5, 2017
- Accepted June 5, 2017
- Published online July 17, 2017.
- Paul Sorajja, MD∗ ()
- Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, Minnesota
- ↵∗Address for correspondence:
Dr. Paul Sorajja, Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis Heart Institute at Abbott Northwestern Hospital, 920 East 28th Street, Minneapolis, Minnesota 55407.
The management of drug-refractory symptoms of obstructive hypertrophic cardiomyopathy has long been debated and is primarily centered on the choice between surgical myectomy and alcohol septal ablation. Decision making in these patients requires consideration of procedural risk, expertise and efficacy, and the long-term impact on patients’ survival. Although there have been numerous reports on these procedures that may help guide decision making, these data continue to be self-reported and voluntary. Greater insight into the real-world experience for these therapies and how they should be applied in practice would be gained from mandatory reporting, akin to other multidisciplinary, transcatheter-based therapies.
Dr. Sorajja has reported that he has no relationships relevant to the contents of this paper to disclose.
- Received May 7, 2017.
- Revision received June 5, 2017.
- Accepted June 5, 2017.
- 2017 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.